Ventaris Surgical Secures $30M Series A For Advanced Kidney Stone Treatment
January 14, 2026, 10:20 am
Ventaris Surgical, a California-based medical device innovator, recently closed a $30 million Series A funding round. Longitude Capital led the investment, with Vensana Capital joining as a new partner. Existing backers also participated, highlighting strong confidence. This substantial capital infusion will propel Ventaris's cutting-edge ureteroscopic system for kidney stone treatment. The system aims to dramatically improve stone clearance, a persistent challenge in common urological procedures. It directly addresses critical issues like surgeon fatigue, complex patient anatomy, and workflow constraints. This funding empowers continued rigorous clinical development, critical regulatory advancements, and strategic market commercialization. The company's technology offers a promising path to better patient outcomes and significantly greater surgical efficiency. It represents a vital step forward in urological care, attracting top-tier venture capital support. This investment validates a critical unmet need.
Ventaris Surgical, a pioneering medical device company, announced a significant financial milestone. The San Carlos, California firm secured $30 million in Series A funding. This capital injection marks a critical step for its innovative kidney stone treatment system. The round saw participation from prominent venture capital firms. Longitude Capital led the Series A. New investor Vensana Capital also joined. Existing backers reaffirmed their commitment. Atypical Ventures, Neotribe Ventures, and Boutique Venture Partners contributed further. This collective support underscores strong market confidence in Ventaris's technology.
The funding round brings new leadership to Ventaris’s board. Varun Gupta of Longitude Capital assumes a board seat. Justin Klein from Vensana Capital also joins. They bring deep industry expertise. Independent board member Amir Abolfathi continues his tenure. This expanded board strengthens the company's strategic direction. It provides invaluable guidance for future growth.
Kidney stones pose a widespread health challenge. Millions worldwide suffer from this painful condition. Urologic interventions for stone removal are common. Yet, these procedures present persistent difficulties. Surgeons face complex variables. Patient anatomy varies greatly. Stone burden differs. Workflow constraints impact efficiency. Surgeon fatigue can influence outcomes. Current tools often struggle with consistent, complete stone clearance. This leaves room for significant improvement in patient care. Incomplete stone removal can lead to repeat procedures. This increases costs and patient discomfort. It highlights a critical unmet need in urology.
Ventaris Surgical directly addresses these challenges. The company develops a novel ureteroscopic system. This next-generation platform aims to revolutionize kidney stone treatment. Its core objective is to achieve better stone clearance. The system helps surgeons overcome existing limitations. It promises more consistent and complete removal. This innovative approach could redefine procedural success. It targets greater efficiency for urologists. It seeks improved outcomes for patients.
The investment fuels Ventaris’s ambitious development plans. Funds will support continued clinical development. This involves rigorous testing and validation. The company will advance crucial regulatory milestones. This ensures compliance and market readiness. Commercialization efforts will also accelerate. Ventaris plans to bring its system to market swiftly and effectively. This multi-pronged strategy ensures comprehensive progress. Each step moves the technology closer to patients and surgeons.
Ventaris's technology offers substantial benefits. It can reduce the burden on surgeons. Enhanced efficiency minimizes procedural time. Improved stone clearance reduces the need for secondary procedures. This translates to better quality of life for patients. It also lowers healthcare system costs. The system's design incorporates ergonomic and workflow considerations. It aims to remove unnecessary friction from operations. Surgeons can then focus purely on complete stone removal. This dedication to practical improvement sets Ventaris apart.
The medical device market is robust. Investment in innovative solutions remains strong. Venture capital firms recognize the immense potential. Healthcare technology offers high returns and societal impact. Ventaris Surgical operates in a vital segment. Kidney stone treatment represents a significant market. Technological advancements drive competitive advantage. Investors seek companies solving real-world medical problems. Ventaris aligns perfectly with this investment thesis. Its solution addresses a clear, widespread clinical need.
CEO Surag Mantri leads Ventaris Surgical. Mantri’s vision centers on improving patient care. The company’s mission is clear: empower surgeons. Provide them with superior tools. Elevate the standard of kidney stone treatment. This leadership drives Ventaris’s pursuit of excellence. The team focuses on innovative engineering. They aim for clinical validation. They target commercial success.
The U.S. healthcare system constantly seeks innovation. Medical devices play a crucial role. They enhance diagnostic capabilities. They improve surgical precision. They accelerate recovery times. Ventaris’s system fits this paradigm. It offers a tangible advancement. It elevates existing treatment paradigms. It stands to benefit countless patients. It also empowers a large body of surgical professionals.
Looking forward, Ventaris Surgical prepares for significant milestones. Clinical trials will demonstrate efficacy and safety. Regulatory approvals will pave the way for market entry. Commercial launch will introduce the system to hospitals. Each step is meticulously planned. The company's trajectory points towards rapid growth. Its technology holds promise for a future of more effective urological care. The $30 million Series A funding is more than capital. It is a vote of confidence. It signifies belief in Ventaris's potential. It supports a vision for better kidney stone treatment. The journey to transform urology has begun.
Ventaris Surgical, a pioneering medical device company, announced a significant financial milestone. The San Carlos, California firm secured $30 million in Series A funding. This capital injection marks a critical step for its innovative kidney stone treatment system. The round saw participation from prominent venture capital firms. Longitude Capital led the Series A. New investor Vensana Capital also joined. Existing backers reaffirmed their commitment. Atypical Ventures, Neotribe Ventures, and Boutique Venture Partners contributed further. This collective support underscores strong market confidence in Ventaris's technology.
The funding round brings new leadership to Ventaris’s board. Varun Gupta of Longitude Capital assumes a board seat. Justin Klein from Vensana Capital also joins. They bring deep industry expertise. Independent board member Amir Abolfathi continues his tenure. This expanded board strengthens the company's strategic direction. It provides invaluable guidance for future growth.
Kidney stones pose a widespread health challenge. Millions worldwide suffer from this painful condition. Urologic interventions for stone removal are common. Yet, these procedures present persistent difficulties. Surgeons face complex variables. Patient anatomy varies greatly. Stone burden differs. Workflow constraints impact efficiency. Surgeon fatigue can influence outcomes. Current tools often struggle with consistent, complete stone clearance. This leaves room for significant improvement in patient care. Incomplete stone removal can lead to repeat procedures. This increases costs and patient discomfort. It highlights a critical unmet need in urology.
Ventaris Surgical directly addresses these challenges. The company develops a novel ureteroscopic system. This next-generation platform aims to revolutionize kidney stone treatment. Its core objective is to achieve better stone clearance. The system helps surgeons overcome existing limitations. It promises more consistent and complete removal. This innovative approach could redefine procedural success. It targets greater efficiency for urologists. It seeks improved outcomes for patients.
The investment fuels Ventaris’s ambitious development plans. Funds will support continued clinical development. This involves rigorous testing and validation. The company will advance crucial regulatory milestones. This ensures compliance and market readiness. Commercialization efforts will also accelerate. Ventaris plans to bring its system to market swiftly and effectively. This multi-pronged strategy ensures comprehensive progress. Each step moves the technology closer to patients and surgeons.
Ventaris's technology offers substantial benefits. It can reduce the burden on surgeons. Enhanced efficiency minimizes procedural time. Improved stone clearance reduces the need for secondary procedures. This translates to better quality of life for patients. It also lowers healthcare system costs. The system's design incorporates ergonomic and workflow considerations. It aims to remove unnecessary friction from operations. Surgeons can then focus purely on complete stone removal. This dedication to practical improvement sets Ventaris apart.
The medical device market is robust. Investment in innovative solutions remains strong. Venture capital firms recognize the immense potential. Healthcare technology offers high returns and societal impact. Ventaris Surgical operates in a vital segment. Kidney stone treatment represents a significant market. Technological advancements drive competitive advantage. Investors seek companies solving real-world medical problems. Ventaris aligns perfectly with this investment thesis. Its solution addresses a clear, widespread clinical need.
CEO Surag Mantri leads Ventaris Surgical. Mantri’s vision centers on improving patient care. The company’s mission is clear: empower surgeons. Provide them with superior tools. Elevate the standard of kidney stone treatment. This leadership drives Ventaris’s pursuit of excellence. The team focuses on innovative engineering. They aim for clinical validation. They target commercial success.
The U.S. healthcare system constantly seeks innovation. Medical devices play a crucial role. They enhance diagnostic capabilities. They improve surgical precision. They accelerate recovery times. Ventaris’s system fits this paradigm. It offers a tangible advancement. It elevates existing treatment paradigms. It stands to benefit countless patients. It also empowers a large body of surgical professionals.
Looking forward, Ventaris Surgical prepares for significant milestones. Clinical trials will demonstrate efficacy and safety. Regulatory approvals will pave the way for market entry. Commercial launch will introduce the system to hospitals. Each step is meticulously planned. The company's trajectory points towards rapid growth. Its technology holds promise for a future of more effective urological care. The $30 million Series A funding is more than capital. It is a vote of confidence. It signifies belief in Ventaris's potential. It supports a vision for better kidney stone treatment. The journey to transform urology has begun.